In Brief
This article was originally published in The Gold Sheet
Executive Summary
Question-based review, or QbR, could spread from generics to new drugs. And that’s the way the patent crumbles: FDA’s new tablet-scoring guidance.
You may also be interested in...
FDA’s Tablet Scoring Final Guidance Requires Generics To Be Same As Brand
Generic industry concerns that scoring conventions could create barriers to entry did not win out in final tablet scoring guidance; FDA says to contact it if the scoring convention is patent protected.
EU’s SCCS Finds Endocrine-Disrupting Evidence Inconclusive In UV Filter Reassessments
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
US FDA Urges COVID-19 Transmission Risk Mitigation In Cell And Gene Therapy Manufacturing
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: